ALLOB (Prod 151002)






About ALLOB (Prod 151002)

ALLOB is an allogeneic cell therapy product for the treatment of delayed union fractures. It is an allogeneic (where cells are derived from a healthy, universal donor, rather than the patient) and osteoblastic (bone-forming) cell therapy product. ALLOB has shown safety and efficacy in preclinical studies and company officials believe that it has the potential to become a first-line treatment for impaired fracture healing, thanks to its minimally invasive percutaneous administration, avoiding the need for surgery. ALLOB also has the potential for systemic applications as in osteogenesis imperfecta, a rare genetic bone disease characterized by bone fragility and fractures. ALLOB has been classified as a tissue engineered product.
Request Product Information

Required



Required

Required



Required

Required



Disclaimer:

OrthopaedicLIST.com is a list of products and services. Every effort is made to keep this listing as accurate and current as possible. Companies and individuals are encouraged to notify us of errors and omissions. We will respond to such messages of correction in a timely fashion, as our workload permits.

We are non-judgmental of products listed. We are not in the business of evaluating products. We have not evaluated these products. We make no representations as to the quality, effectiveness, suitability or appropriateness of any of the products listed.

As an important component of the service function of OrthopaedicLIST.com, some products continue to be listed that are no longer manufactured and may not be available. We will identify them as such when possible. This allows users to find special instruments and/or components for removal, modification, and/or revision of those products.